[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St. Joseph's Centre, Poland\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100606124","pulsed-field-ablation-with-concomitant-radiofrequency-cardioneuroablation-in-patients-with-paroxysmal-atrial-fibrillation-100606124",false,"NCT07171463","Pulsed Field Ablation With Concomitant Radiofrequency Cardioneuroablation in Patients With Paroxysmal Atrial Fibrillation","Evaluation of the Safety and Efficacy of Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation Using Point-by-Point Bipolar Pulsed Field Ablation Combined With Thermal Ablation of the Superior Paraseptal Parasympathetic Ganglion Region","PFACNA-AF","Inclusion Criteria:\n\n* Age ≥18 years\n* Documented paroxysmal atrial fibrillation (AF) lasting ≥30 seconds on ECG or Holter monitoring\n* Willingness and ability to provide written informed consent\n* Life expectancy \\>1 year\n\nExclusion Criteria:\n\n* Persistent AF lasting \\>7 days or long-standing AF \\>1 year\n* Secondary AF due to electrolyte imbalance, thyroid disease, alcohol abuse, or other non-cardiac causes\n* Left atrial anteroposterior diameter ≥45 mm on transthoracic echocardiography\n* Clinically significant coexisting arrhythmias other than AF\n* Significant valvular heart disease or valve prosthesis\n* Chronic heart failure NYHA class III\u002FIV\n* Previous AF or atrial flutter ablation\n* Prior closure of atrial septal defect or left atrial appendage\n* Atrial myxoma\n* Implanted pacemaker or defibrillator\n* History of pericarditis\n* Congenital heart disease\n* Coagulopathy or bleeding disorders\n* Contraindications to oral anticoagulation\n* Contraindications to CT or MRI\n* Pregnancy or breastfeeding\n* Body Mass Index \\>30\n* History of organ transplantation\n* Severe pulmonary disease\n* Estimated Glomerular Filtration Rate \\\u003C30 mL\u002Fmin\u002F1.73 m²\n* Active malignancy\n* Significant infection\n* Life expectancy \\\u003C1 year\n* Psychiatric disorders preventing study participation\n* Refusal or inability to provide informed consent","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","Pulsed-field ablation (PFA) is a novel, non-thermal method for the treatment of atrial fibrillation (AF). It uses short, high-voltage electrical pulses to selectively ablate cardiomyocytes. PFA has demonstrated a high safety profile with reduced complication rates compared to thermal ablation.\n\nThermal ablation of parasympathetic ganglia during conventional pulmonary vein isolation (PVI) may improve long-term procedural outcomes by reducing AF recurrence. However, due to its non-thermal nature, PFA may not significantly affect cardiac autonomic innervation, which could be clinically relevant in vagally mediated AF or tachycardia-bradycardia syndrome.\n\nThis randomized study compares two strategies: (1) PFA-only PVI, and (2) PFA combined with selective thermal ablation (radiofrequency energy) of the superior paraseptal parasympathetic ganglion. The primary objective is to evaluate whether adjunctive thermal ablation improves clinical outcomes and reduces intraprocedural bradyarrhythmic events.",[27],"Atrial Fibrillation (Paroxysmal)",[29,30,31],"Atrial fibrillation","Pulsed Field Ablation","Cardioneuroablation","RECRUITING","2025-09-07",{"date":35,"type":36},"2025-09-12","ACTUAL",{"date":38,"type":36},"2025-05-26",{"date":40,"type":21},"2026-09-30",{"name":42,"class":43},"St. Joseph's Centre, Poland","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100520584","cardioneuroablation-vs-pulmonary-vein-isolation-in-treatment-of-paroxysmal-atrial-fibrillation-100520584","NCT06058468","Cardioneuroablation vs Pulmonary Vein Isolation in Treatment of Paroxysmal Atrial Fibrillation","Cardioneuroablation of Right Anterior Ganglionated Plexus vs Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation and Enhanced Vagal Tone","Inclusion Criteria:\n\n* Paroxysmal atrial fibrillation documented in ECG or Holter monitoring\n* Deceleration capacity \\>7.5ms\n* Life expectancy more than 1 year\n* Age ≥18 years\n\nExclusion Criteria:\n\n* Permanent AF lasting more than one year or persistent AF lasting more than 7 days\n* AF secondary to electrolyte imbalance, thyroid disease, alcohol abuse, or other non-heart related causes\n* Anteroposterior dimension of the left atrium in the echocardiography ≥43mm\n* Clinically significant arrhythmias other than AF\n* Significant valvular disease\n* Valve prosthesis\n* Heart failure III or IV Class in New York Heart Association Classification\n* Previous ablation of atrial fibrillation or atrial flutter\n* History of a patent foramen ovale\u002Fatrial septal defect closure\n* History of left atrial appendage closure\n* Atrial myxoma\n* Presence of a cardiac pacemaker, defibrillator or cardiac resynchronization therapy device\n* History of pericarditis\n* Congenital heart disease\n* History of bleeding or coagulation disorders\n* Contraindications to oral anticoagulation\n* Contraindications to computed tomography or magnetic resonance imaging\n* Pregnancy or breast-feeding\n* BMI\\>31\n* History of transplantation\n* Severe lung disease\n* Chronic renal failure defined as estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin\u002Fm2\n* Cancer\n* Significant infection\n* Life expectancy less than one year\n* Mental disorders\n* Lack of informed consent to participate in the trial",{"count":53,"type":21},160,[24],"The goal of this study is to compare effectiveness of cardioneuroablation of right anterior ganglionated plexus and pulmonary vein isolation in patients with enhanced vagal tone expressed as deceleration capacity \\>7.5ms.",[57],"Atrial Fibrillation Paroxysmal",[59,60,31],"Atrial Fibrillation","Vagally-mediated","NOT_YET_RECRUITING","2023-09-27",{"date":64,"type":36},"2023-09-29",{"date":66,"type":21},"2024-01",{"date":68,"type":21},"2029-06",{"name":42,"class":43},""]